Reata Pharmaceuticals, Inc. (RETA) Releases Quarterly Earnings Results, Misses Estimates By $0.11 EPS

Reata Pharmaceuticals, Inc. (NASDAQ:RETA) issued its quarterly earnings data on Monday. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.11), Briefing.com reports. The company had revenue of $12.60 million during the quarter, compared to analysts’ expectations of $12.54 million. Reata Pharmaceuticals’s quarterly revenue was up .0% compared to the same quarter last year.

Reata Pharmaceuticals (NASDAQ RETA) opened at $24.42 on Wednesday. The company has a quick ratio of 1.34, a current ratio of 1.34 and a debt-to-equity ratio of -0.09. Reata Pharmaceuticals has a 52-week low of $18.51 and a 52-week high of $40.88.

COPYRIGHT VIOLATION NOTICE: “Reata Pharmaceuticals, Inc. (RETA) Releases Quarterly Earnings Results, Misses Estimates By $0.11 EPS” was posted by Week Herald and is the sole property of of Week Herald. If you are accessing this report on another site, it was illegally stolen and reposted in violation of international trademark & copyright law. The legal version of this report can be read at https://weekherald.com/2017/11/15/reata-pharmaceuticals-inc-reta-releases-quarterly-earnings-results-misses-estimates-by-0-11-eps.html.

RETA has been the subject of a number of recent analyst reports. Zacks Investment Research downgraded Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, July 18th. Piper Jaffray Companies raised their price objective on Reata Pharmaceuticals from $53.00 to $60.00 and gave the stock a “buy” rating in a research report on Monday, July 24th. Citigroup Inc. reissued a “buy” rating and set a $87.00 price objective (up from $39.00) on shares of Reata Pharmaceuticals in a research report on Tuesday, July 25th. Stifel Nicolaus reissued a “buy” rating and set a $50.00 price objective (up from $38.00) on shares of Reata Pharmaceuticals in a research report on Tuesday, July 25th. Finally, Robert W. Baird reissued an “outperform” rating and set a $47.00 price objective (up from $43.00) on shares of Reata Pharmaceuticals in a research report on Tuesday, July 25th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $54.71.

About Reata Pharmaceuticals

Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.

Receive News & Ratings for Reata Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply